Post hoc trial analysis reveals early albuminuria reductions from canagliflozin predict long-term kidney and heart health in type 2 diabetes, highlighting its prognostic value.
In people with type 2 diabetes and CKD, use of canagliflozin results in early, sustained reductions in albuminuria, which were independently associated with long-term kidney and cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Oshima et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: